Immunoassay Design and Development

Dr. Masha Fridkis-Hareli is an immunologist, consultant, and inventor with over twenty years of experience in academia and industry. She is a founder and president of Accelerating Translational Research (ATR), LLC, a translational research company providing scientific consulting and laboratory services in assay development for immune disorders. Fridkis-Hareli holds a BA from the Technion-Israel Institute of Technology, an MS from Hebrew University, and a PhD from the Weizmann Institute of Science in Israel. During her postdoctoral training at Harvard University, she designed and developed a group of novel compounds for treatment of autoimmune diseases currently in phase II clinical trials. After serving as principal investigator at the Dana Farber Cancer Institute, Fridkis-Hareli transitioned to industry where she held a variety of positions with increasing responsibilities at Resolvyx Pharmaceuticals, Charles River Laboratories, Taligen Therapeutics, and Alexion Pharmaceuticals. Fridkis-Hareli is a co-author of over 100 publications and a co-inventor of seventeen issued patents. She is an adjunct professor at Northeastern University, Worcester Polytechnic Institute, and Framingham State University, where she teaches courses in biotechnology and immunology at the graduate biotechnology programs.